Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) today announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV) (the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Marinus Pharmaceuticals (MRNS) PT Raised to $22 at Ladenburg ThalmannDecember 11, 2018 7:06 AM Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum DepressionDecember 10, 2018 7:30 AM